Overview of Sucral O

Sucral O is defined as a specialized combination product that integrates two distinct synthetic derivative compounds into a single viscous oral suspension or gel for oral administration. This medicine is a combination of a Cytoprotective Agent and a Local Anesthetic, designed specifically to address irritation and injury of the upper gastrointestinal tract lining. Unlike simple single-action treatments, its therapeutic value is rooted in its dual-action approach, offering both a physical defense mechanism and immediate sensory relief upon contact with the affected mucosa.

Property	Description
Active Ingredients	Sucralfate and Oxetacaine
Form	Oral suspension or Gel
Pharmacological Class	Cytoprotective Agent and Local Anesthetic Combination
Regulatory Status	Typically available by prescription only

What Type of Medicine is Sucral O?

Sucral O belongs to the high-level pharmacological class of an Antiulcer Drug combined with a Local Anesthetic. The medicine's classification relates to its ability to address both the irritation and the resulting discomfort simultaneously. The identity of this medicine as a combination product distinguishes it from therapies that rely only on systemic acid suppression. The principal component, Sucralfate, is an effective cytoprotective agent, supporting the medicine's role in providing physical protection to the damaged lining, a key mechanism clinically recognized for supporting mucosal repair.

Active Ingredients, Form, and General Benefit

The active ingredients in Sucral O are Sucralfate and Oxetacaine. The viscous oral suspension or gel form is essential because it is specifically designed to maximize contact time, allowing the Sucralfate component to physically coat the irritated mucosal surface upon oral administration, forming a protective barrier. Furthermore, the inclusion of Oxetacaine provides a rapid, local numbing effect to relieve discomfort. The anesthetic provides immediate symptomatic relief, which is beneficial for patient comfort while the cytoprotective effect promotes healing. The general benefit of this pairing is achieving both immediate pain relief and ongoing mucosal protection simultaneously, making it suitable for managing painful irritation of the digestive tract lining.

Regulatory References

WHO Essential Medicines List

Therapeutic Uses of Sucral O

What Sucral O Treats: Main Uses and Benefits

The therapeutic application of this medicine is generally focused on addressing symptoms related to physical discomfort and inflammatory or irritative states in the upper gastrointestinal tract. The primary use is to provide supportive relief when symptoms associated with acidic irritation or mucosal damage are present, which cause significant discomfort.

Easing Localized Digestive Discomfort

This medicine is commonly used across conditions characterized by periods of heightened symptoms such as peptic ulcers, gastritis, and certain cases of reflux. It helps address symptom clusters that may become intense or disruptive, specifically those related to physical discomfort and inflammatory or irritative states. The use of this medication is relevant in contexts marked by increased discomfort or tension associated with conditions like duodenal ulcers.

The medicine is relevant for easing symptoms related to inflammatory or irritative states associated with certain conditions like ulcers, gastritis, and esophageal irritations. It contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Supports Management of Irritative Pain

Supportive Relief for Symptom Stabilization

Sucral O is applied in clinical settings that involve acute or unstable symptom patterns, such as flare-ups of discomfort or severe burning, where short-term symptomatic assistance is needed. This medicine may assist with addressing symptoms that interfere with daily functioning, providing supportive relief when symptoms interfere with routine activities. It is often used during phases when symptoms become more noticeable to offer support that helps ease the overall symptom burden.

Eligibility and Restrictions for Use

Who Can and Cannot Use Sucral O? (Official Eligibility Rules)

Official regulatory guidelines strictly define the populations permitted or restricted from using the Sucral O combination medicine (Sucralfate and Oxetacaine).

Contraindicated and Restricted Use

Population Status	Eligibility Restriction
Absolute Contraindication	The medicine is contraindicated in patients with a known hypersensitivity to sucralfate or oxetacaine or any excipient. Use is also contraindicated in patients with or suspected of having intestinal obstruction or severe constipation.
Conditional Use	Patients with Chronic Kidney Disease (CKD) or renal impairment must use the medicine with caution and often for limited durations due to the risk of aluminum accumulation from the sucralfate component.

Age and Physiological Restrictions

Adults (18 years and older) are the population for whom use is established. Safety and effectiveness have not been established in pediatric patients (under 18 years), leading to a general restriction in this age group. While older adults may use the medicine, caution is advised due to the potential for reduced renal function.

For pregnant and breastfeeding women, use is generally not recommended or advised with caution due to insufficient safety data documented for the combination product.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Documented Interaction Patterns

The primary documented interaction pattern for Sucral O, whose profile is governed by the Sucralfate component, is a nonsystemic pharmacokinetic interaction . This effect results in the reduced systemic exposure (bioavailability) of several co-administered oral medications by physically binding to them in the gastrointestinal tract. Regulatory sources list specific agents whose absorption is reduced, including Digoxin, Phenytoin, Cimetidine, Ranitidine, L-thyroxine (Levothyroxine), Ketoconazole, and fluoroquinolone antibiotics.

Administration Requirements and Restrictions

To manage the reduced bioavailability of these critical oral medications, official labeling mandates a timing-based administration separation. The concomitant medication must be administered two hours before Sucral O to ensure appropriate systemic absorption. Conversely, aluminum-containing antacids and Sucral O must be separated by at least one-half hour to prevent an additive aluminum exposure risk.

Population-Specific Caution

This additive aluminum burden creates a population-specific interaction caution for patients with chronic renal failure or those receiving dialysis. Due to impaired aluminum excretion, the risk of aluminum accumulation and toxicity is increased in this specific patient population.

Mechanism of Action

Physical Barrier Formation and Cytoprotection

This domain involves Sucralfate, an agent that acts locally within the digestive system. In the stomach's acidic environment, it undergoes polymerization, forming a viscous, adhesive substance. This substance binds selectively to proteins (albumin and fibrinogen) at sites of mucosal discontinuity, resulting in the formation of a physical layer that prevents contact with luminal contents, including acid, pepsin, and bile salts. It further engages cellular regulation mechanisms by stimulating the production of endogenous prostaglandins and growth factors, modifying early molecular steps that influence cellular renewal pathways.

Local Sensory Impulse Modulation

This mechanistic domain is governed by Oxetacaine (or Oxethazaine), a local surface anesthetic. This compound engages sensory signaling pathways by diminishing the conduction of nerve impulses directly at the mucosal surface. It achieves this by decreasing the cell membrane's permeability to sodium ions. This molecular interaction results in the suppression of local sensory afferent signaling, altering the transmission of nociceptive input from the mucosal surface.

Dosage and Administration Information

How to Use Sucralfate (Sucral O/Carafate)

Instructions for using Sucralfate, the active ingredient in Sucral O, define a specific procedural structure based on the drug's approved administration requirements.

Route and Dosage

Sucralfate is for oral use only (swallowed). It must not be administered intravenously. The standard dosing is 1 gram (g) per dose.

Condition	Dosage Amount	Frequency
Acute Treatment (Active Ulcer)	1 g	Four times daily (QID)
Maintenance Therapy (Ulcer Prophylaxis)	1 g	Two times daily (BID)

Timing and Administration

The medicine is specifically instructed to be taken on an empty stomach. This means the dose should be taken 1 hour before or 2 hours after meals.

To ensure the medicine works as intended, it must be separated from many other substances:

Antacids should not be taken within 30 minutes of a Sucralfate dose.
Most other oral prescription medications should be spaced at least 2 hours before or after the Sucralfate dose.

If using the oral suspension, the bottle must be thoroughly shaken before each dose is measured. Acute treatment is typically continued for 4 to 8 weeks or until healing is confirmed. Special caution is advised for dose selection in elderly patients due to the higher likelihood of decreased kidney function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sucral O

This section provides an overview of the research that has explored the use of the combination of Sucralfate and Oxetacaine, focusing on the structures of the studies, the outcomes they measured, and areas where certainty remains low.

Evidence for Use in Active Duodenal Ulcer Healing

Research has been studied for conditions involving injury to the lining of the digestive tract, particularly active duodenal ulcers. The evidence base includes Randomized Controlled Trials (RCTs) and Comparative Clinical Studies. Research primarily focused on the Sucralfate component, with studies monitoring outcomes such as ulcer healing rates and the assessment of associated discomfort. These studies included Adults with endoscopically confirmed ulcers.

Evidence suggests that findings indicate that in these specific trials, the ulcer healing patterns were similar to some other anti-ulcer treatments studied during the same period. The inclusion of Oxetacaine was evaluated in studies examining short-term symptom changes and how discomfort evolved in the observed populations. Comparative evidence is lacking for the Sucralfate and Oxetacaine combination product specifically, especially when contrasted with other established treatments.

Evidence for Symptomatic Relief in Acid-Related Conditions

This medicine was studied for its role in providing relief from symptoms in conditions involving periods of heightened symptoms such as gastritis and certain acid-peptic disorders. The research base includes Clinical Trials and smaller studies, often applied in research contexts involving fluctuating or unstable symptoms in populations of Adults experiencing various forms of digestive tract irritation.

The evidence provides insight into symptom patterns observed in the studies and monitors changes in patient-reported outcomes describing perceived discomfort. Fewer large, dedicated RCTs have been conducted comparing this combination product specifically to other established anti-acid treatments for chronic or long-term management of these conditions. Follow-up durations were limited in many of the trials focusing on symptom effects, meaning there is less data available on long-term effects or durability of the symptomatic relief.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Sucral O (FAQ)

Q: Does Sucral O contain any active ingredients besides Sucralfate?

Regulatory documents state that Sucral O contains Sucralfate as its main active ingredient. Additionally, it contains Oxetacaine, which is included to help relieve pain associated with certain conditions. The combination of these two ingredients is detailed in the official product information.

Q: Is Sucral O used for treating stomach pain?

Official information indicates that Sucral O is used to treat conditions such as duodenal ulcers, stomach ulcers, gastritis, and esophagitis. These conditions are often associated with stomach or abdominal pain. The medicine is indicated for treating these conditions, which may help manage associated discomfort and symptoms, according to the product's official indications.

Q: What is the primary action of Sucralfate in Sucral O?

According to official product information, Sucralfate works by forming a protective coating over ulcers or irritated areas in the digestive tract. This barrier shields the affected tissue from acid and digestive enzymes, allowing the affected areas the opportunity to heal. This primary action helps to manage conditions like ulcers and inflammation.

Q: How does Oxetacaine contribute to the effect of Sucral O?

The official product information specifies that Oxetacaine is a local anesthetic included in the formulation of Sucral O. Its intended action is to temporarily numb the area, which may help relieve the pain and discomfort associated with ulcers, esophagitis, or other gastrointestinal irritations. This complements the protective action of Sucralfate.

Q: Can I take Sucral O while breastfeeding?

The regulatory documents advise that caution should be exercised when considering the use of Sucral O during breastfeeding. Official information indicates that the potential benefits should be weighed against any potential risks to the infant before a decision is made. Detailed guidance on this matter can be found in the product's official prescribing information.

Q: Can Sucral O be used to treat acid reflux (heartburn)?

Studies and official information indicate that Sucral O is used for conditions including esophagitis, which is often related to chronic acid reflux. While it doesn't directly prevent acid production, its protective action on the esophagus is intended to help manage symptoms and address damage related to conditions such as esophagitis, as indicated by official product labeling.

How should Sucral O be stored and disposed of?

How to Store and Dispose of Sucral O Oral Suspension

Sucral O oral suspension must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). It is essential that the medicine not be frozen and is kept away from excess heat and moisture. Keep the container tightly closed in its original packaging.

Handling and Protection

The product must be stored out of the sight and reach of children. Once the bottle has been opened, the medicine may need to be used within a specific in-use period, such as four weeks, as determined by the formulation's stability.

Disposal

Disposal of unused or expired Sucral O should prioritize a drug take-back program. If a take-back option is unavailable, the suspension should be mixed with an undesirable substance, placed in a sealed container, and then discarded into the household trash. Do not flush the medicine down the toilet unless directed otherwise.

Sucral O